Eli Lilly's orforglipron achieves key trial success, advancing obesity and diabetes treatment
TL;DR Summary
Eli Lilly's oral GLP-1 receptor agonist, orforglipron, successfully met primary and secondary endpoints in a Phase 3 trial, showing significant weight loss and A1C reduction in adults with obesity or overweight and type 2 diabetes, leading to plans for global regulatory submissions.
- Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity Eli Lilly and Company
- Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval CNBC
- Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals The Wall Street Journal
- Eli Lilly’s weight-loss pill meets target in key diabetes trial Financial Times
- Lilly pill cuts body weight by 10.5% in patients with type 2 diabetes Reuters
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
10 min
vs 11 min read
Condensed
98%
2,009 → 42 words
Want the full story? Read the original article
Read on Eli Lilly and Company